Overview
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Description
Main enrolled criteria:
Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using
Eligibility
Inclusion Criteria:
- ≥18,Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- HER 2 Insertion or Amplification
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria:
- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women